- Home
- KO vs ABBV Comparison
KO vs ABBV Comparison
Compare KO & ABBV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KO | ABBV |
|---|---|---|
| Founded | 1886 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 326.0B | 358.5B |
| IPO Year | 2003 | 2012 |
Fundamental Metrics
Financial Performance| Metric | KO | ABBV |
|---|---|---|
| Price | $80.96 | $210.48 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 18 |
| Target Price | $84.13 | ★ $253.71 |
| AVG Volume (30 Days) | ★ 12.1M | 5.0M |
| Earning Date | 04-28-2026 | 04-29-2026 |
| Dividend Yield | 2.69% | ★ 3.39% |
| EPS Growth | ★ 23.58 | N/A |
| EPS | ★ 0.91 | 0.39 |
| Revenue | $47,941,000,000.00 | ★ $61,160,000,000.00 |
| Revenue This Year | $5.29 | $11.87 |
| Revenue Next Year | $1.77 | $8.12 |
| P/E Ratio | ★ $88.49 | $540.92 |
| Revenue Growth | 1.87 | ★ 8.57 |
| 52 Week Low | $65.35 | $180.25 |
| 52 Week High | $81.69 | $244.81 |
Technical Indicators
Market Signals| Indicator | KO | ABBV |
|---|---|---|
| Relative Strength Index (RSI) | 68.48 | 55.06 |
| Support Level | $74.31 | $203.48 |
| Resistance Level | N/A | $213.66 |
| Average True Range (ATR) | 1.20 | 5.38 |
| MACD | 0.29 | 1.17 |
| Stochastic Oscillator | 90.08 | 81.63 |
Price Performance
Historical ComparisonAbout KO Coca-Cola Company (The)
Founded in 1886, Atlanta-headquartered Coca-Cola is the world's largest nonalcoholic beverage company, with a strong portfolio of 200 brands covering key categories including carbonated soft drinks, water, sports, energy, juice, and coffee. Together with bottlers and distribution partners, the company sells finished beverage products bearing Coca-Cola and licensed brands through retailers and food-service locations in more than 200 countries and regions globally. Coca-Cola generates around 60% of its total revenue overseas, with sizable contributions from emerging economies in Latin America and Asia-Pacific.
About ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.